Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Curcumin Multiple Myeloma- as Evidence-based, Integrative Therapy

Share Button

“Altogether, these results support clinical trials including curcumin in association (integrative) with standard (MM) therapy.”

The challenge for every myeloma patient is to achieve the deepest, longest remission possible while sustaining the least amount of collateral damage (side effects) possible. Numerous studies document the anti-MM and integrative efficacy of curcumin.

I am both a long-term multiple myeloma survivor and MM cancer coach.  I have supplemented with curcumin (CU) since 2006. I live an evidence-based, non-toxic, anti-MM lifestyle through nutrition, supplementation (curcumin, others), bone health, detox, mind-body and more.

This link is to the Google search page for “curcumin in myeloma.” Whether it is an article authored by Pat Killingsworth or Margaret from Margaret’s Corner, or PubMed, curcumin is documented to be both cytotoxic to myeloma in addition to being “integrative”  or enhancing the action of Velcade, Revlimid, and Thalidomide.

A common question asked by multiple myeloma patients considering supplementing with curcumin is about the daily dose. Unfortunately, I have several possible answers:

  • The research into MM and curcumin usually refers to a “time and dose dependent manner.” Meaning, the more curcumin the patient takes, the more MM cells are killed.
  • I read about patients with active MM taking doses at many different amounts, from 1 gram a day up to 8 grams a day.
  • For comparison, I take 400 milligrams. My MM is not active therefore I take a maintenance dose. To clarify, 1000 milligrams = 1 gram.
  • To confuse things even more, many brands of curcumin are more bioavailable than others. Bioavailability means absorption in the blood stream. Bioprene is known to enhance the bioavailability of curcumin.

The bottom line, in my opinion anyway, is that MM patients must include evidence-based, non-toxic therapies such as curcumin, into their therapy plan.

The study linked below as an ideal example of integrative cancer therapy. That is to say, combining both conventional myeloma therapies (thalidomide/ bortezomib/Velcade with non-conventional therapy such as curcumin.)

If you would like to learn more about other evidence-based, integrative therapies that integrate with and/or fight multiple myeloma, click the button below to sign up for a FREE webinar by clicking the blue button below:

Have you been diagnosed with multiple myeloma? What stage? Have you begun therapy? Scroll down the page, post a question or comment and will reply to you ASAP.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

CU enhances the cytotoxic and chemo-sensitizing effects of lenalidomide in human multiple myeloma cells

Background: CU, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model…

Conclusion: CU exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent.

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.

“Multiple myeloma (MM), a plasma cell malignancy, remains incurable despite the development of new therapies. CU anti-tumor effects were previously characterized in multiple myeloma, however only few MM cell lines were included in these studies.

Since myeloma is a heterogeneous disease it is important to address the impact of myeloma molecular heterogeneity in CU cell death induction.

In the present study, a large panel of human myeloma cell lines (HMCLs) (n = 29), representing the main molecular MM subgroups, was screened for CU sensitivity. We observed that CU cell death induction was heterogeneous, of note 16 HMCLs were highly sensitive to CU (LD50 < 20.5 μM), 6 HMCLs exhibited intermediate LD50 values (20.5 μM ≤ LD50 < 32.2 μM) and only 7 HMCLs were weakly sensitive (35 < LD50 < 56 μM).

Cell lines harboring the t(11;14) translocation were less sensitive (median LD50 32.9 μM) than non-t(11;14) (median LD50 17.9 μM), which included poor prognosis t(4;14) and t(14;16) cells.

Interestingly, CU sensitivity was not dependent on TP53 status. For the first time we showed that primary myeloma cells were also sensitive, even those displaying del(17p), another poor prognosis factor. We also unravel the contribution of anti-apoptotic Bcl-2 family molecules in CU response.

We found that down-regulation of Mcl-1, an essential MM survival factor, was associated with CU-induced cell death and its knockdown sensitized myeloma cells to CU, highlighting Mcl-1 as an important target for CU-induced apoptosis. Altogether, these results support clinical trials including CU in association with standard therapy.”


Leave a Comment:

Add Your Reply